| Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer I Vergote, CG Tropé, F Amant, GB Kristensen, T Ehlen, N Johnson, ... New England Journal of Medicine 363 (10), 943-953, 2010 | 2863* | 2010 |
| Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer MR Mirza, BJ Monk, J Herrstedt, AM Oza, S Mahner, A Redondo, ... New England Journal of Medicine 375 (22), 2154-2164, 2016 | 2543 | 2016 |
| Endometrial cancer F Amant, P Moerman, P Neven, D Timmerman, E Van Limbergen, ... The Lancet 366 (9484), 491-505, 2005 | 2461 | 2005 |
| Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer J Ledermann, P Harter, C Gourley, M Friedlander, I Vergote, G Rustin, ... New England Journal of Medicine 366 (15), 1382-1392, 2012 | 2175 | 2012 |
| Niraparib in patients with newly diagnosed advanced ovarian cancer A González-Martín, B Pothuri, I Vergote, R DePont Christensen, ... New England Journal of Medicine 381 (25), 2391-2402, 2019 | 1894 | 2019 |
| Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised … J Ledermann, P Harter, C Gourley, M Friedlander, I Vergote, G Rustin, ... The lancet oncology 15 (8), 852-861, 2014 | 1762 | 2014 |
| Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial E Pujade-Lauraine, F Hilpert, B Weber, A Reuss, A Poveda, G Kristensen, ... Journal of clinical oncology 32 (13), 1302-1308, 2014 | 1746 | 2014 |
| Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised … E Pujade-Lauraine, JA Ledermann, F Selle, V Gebski, RT Penson, ... The lancet oncology 18 (9), 1274-1284, 2017 | 1745 | 2017 |
| Olaparib plus bevacizumab as first-line maintenance in ovarian cancer I Ray-Coquard, P Pautier, S Pignata, D Pérol, A González-Martín, ... New England Journal of Medicine 381 (25), 2416-2428, 2019 | 1718 | 2019 |
| Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial RL Coleman, AM Oza, D Lorusso, C Aghajanian, A Oaknin, A Dean, ... The Lancet 390 (10106), 1949-1961, 2017 | 1700 | 2017 |
| ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma N Concin, X Matias-Guiu, I Vergote, D Cibula, MR Mirza, S Marnitz, ... International Journal of Gynecologic Cancer 31 (1), 2021 | 1617 | 2021 |
| Epithelial ovarian cancer S Lheureux, C Gourley, I Vergote, AM Oza The Lancet 393 (10177), 1240-1253, 2019 | 1503 | 2019 |
| Randomized intergroup trial of cisplatin–paclitaxel versus cisplatin–cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results MJ Piccart, K Bertelsen, K James, J Cassidy, C Mangioni, E Simonsen, ... Journal of the National Cancer Institute 92 (9), 699-708, 2000 | 1313 | 2000 |
| ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease N Colombo, C Sessa, A du Bois, J Ledermann, WG McCluggage, ... Annals of oncology 30 (5), 672-705, 2019 | 1178 | 2019 |
| Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and … J Bonneterre, B Thurlimann, JFR Robertson, M Krzakowski, L Mauriac, ... Journal of Clinical Oncology 18 (22), 3748-3757, 2000 | 1135 | 2000 |
| Terms, definitions and measurements to describe the sonographic features of adnexal tumors: a consensus opinion from the International Ovarian Tumor Analysis (IOTA) Group D Timmerman, L Valentin, TH Bourne, WP Collins, H Verrelst, I Vergote Ultrasound in Obstetrics and Gynecology: The Official Journal of the …, 2000 | 1114 | 2000 |
| Sentinel node dissection is safe in the treatment of early-stage vulvar cancer AGJ Van der Zee, MH Oonk, JA De Hullu, AC Ansink, I Vergote, ... Journal of clinical oncology 26 (6), 884-889, 2008 | 935 | 2008 |
| Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the … J Pfisterer, M Plante, I Vergote, A du Bois, H Hirte, AJ Lacave, U Wagner, ... Journal of Clinical Oncology 24 (29), 4699-4707, 2006 | 876 | 2006 |
| Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment A Howell, JFR Robertson, J Quaresma Albano, A Aschermannova, ... Journal of Clinical Oncology 20 (16), 3396-3403, 2002 | 875 | 2002 |
| Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma I Vergote, J De Brabanter, A Fyles, K Bertelsen, N Einhorn, P Sevelda, ... The lancet 357 (9251), 176-182, 2001 | 800 | 2001 |
